CD79A and COVID-19: In their pilot study, they demonstrated, through simulated in vitro digestion, that anti-SARS-CoV-2 IgA and IgG antibodies in breast milk from women infected and vaccinated against COVID-19 can survive digestion, with levels remaining above cut-off values even after the intestinal phase of digestion [105].